Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $42 Price Target
RCKTApril 9, 2025
Read more →BMO Capital Initiates Coverage On Rocket Pharmaceuticals with Outperform Rating, Announces Price Target of $50
RCKTMarch 12, 2025
Read more →Scotiabank Maintains Sector Outperform on Rocket Pharmaceuticals, Raises Price Target to $52
RCKTMarch 3, 2025
Read more →Goldman Sachs Maintains Neutral on Rocket Pharmaceuticals, Lowers Price Target to $15
RCKTMarch 3, 2025
Read more →Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $36
RCKTMarch 3, 2025
Read more →Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $54
RCKTFebruary 28, 2025
Read more →Needham Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $42
RCKTFebruary 28, 2025
Read more →Rocket Pharmaceuticals Q4 2024 GAAP EPS $(0.62) Beats $(0.71) Estimate
RCKTFebruary 27, 2025
Read more →Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Maintains $39 Price Target
RCKTNovember 19, 2024
Read more →Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst
RCKTRocket Pharmaceuticals reveals RP-A501 Phase 1 data for Danon disease, showing durable efficacy, reduced cardiac biomarkers, and improved heart health.
November 19, 2024
Read more →Leerink Partners Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $44
RCKTNovember 19, 2024
Read more →Cantor Fitzgerald Reiterates Overweight on Rocket Pharmaceuticals, Maintains $65 Price Target
RCKTNovember 19, 2024
Read more →Needham Reiterates Buy on Rocket Pharmaceuticals, Maintains $52 Price Target
RCKTNovember 19, 2024
Read more →Rocket Pharmaceuticals Announces New England Journal Of Medicine Publication Of Phase 1 RP-A501 Long-Term Data And Presents At Late-Breaking Scientific Sessions At 2024 American Heart Association Conference; RP-A501 Demonstrated Safety And Meaningful Effi
RCKTNovember 18, 2024
Read more →